About Acyl-coenzyme A diphosphatase NUDT19
Acyl-coenzyme A diphosphatase NUDT19 (NUDT19) is a protein
from Homo sapiens identified by UniProt accession
A8MXV4, 375 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Acyl-coenzyme A diphosphatase NUDT19 |
| UniProt accession | A8MXV4 |
| Gene | NUDT19 |
| Organism | Homo sapiens |
| Length | 375 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- creatinine measurement · score 0.22
- hemoglobin measurement · score 0.22
- cystatin C measurement · score 0.17
- mean corpuscular volume · score 0.16
- urinary metabolite measurement · score 0.13
- genetic disorder · score 0.12
- mean corpuscular hemoglobin concentration · score 0.07
- Red cell distribution width · score 0.04
- bleeding disorder, platelet-type, 24 · score 0.03
- platelet-type bleeding disorder 15 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A8MXV4-F1 | alphafold | PREDICTED | 87.80 | — |
Amino-acid sequence (375 residues)
MSSSLRPGPS RWRRAASIVL AAGWSRPETA TPPSRPPPAE GFRLLLLQRS PHQGFMPGAH VFSGGVLDAA DRSADWLGLF APHHGPPRFG LGPAPFSRTA FPSLPDTDDH KTDNTGTLPE DVAFRICAVR EAFEEAGVLL LRPRTSPPGP APGPGLALEP PPGLASWRDR VRQDPRHFLR LCAHLDCTPD IWALHNWSAW LTPFLRGTTR RFDTAFFLCC LREPPPVYPD LAEVVGYQWS SPSEATESFL SKEIWLPPPQ FYEVRRLANF ASLSDLHKFC LGRALEGLER WLPIILLTAD GMVHLLPGDE LYLEDSDFLE NLMSTEKKTE EIMKEGKQFH RIVTYHRHLY DIHVTVQPKY KHVYPKNSVV RKSHL
Explore Acyl-coenzyme A diphosphatase NUDT19 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets